Clinical Trials Browser

Phase 1/2 × Interventional × HER2-positive Gastric Cancer × Clear all

NCT06572319 2024-08-27

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Phase 1/2 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1/2 Unknown

Gastrointestinal

HER2-positive Gastric Cancer